Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
MSH3
REST API REST API
Homo sapiens
MSH3 is differentially expressed in 253 experiments: 107 organism parts: liver, lung, ... (105 more);, 182 disease states: normal, prostate carcinoma, ... (180 more);, 81 cell types 369 cell lines 27 compound treatments and 77 other conditions.
Synonyms DUP, MRP1
Orthologs F1MLH1_BOVIN (Bos taurus)   MSH3 (Saccharomyces cerevisiae)   msh3 (Danio rerio)   E1C1F8_CHICK (Gallus gallus)   Msh3 (Mus musculus)   ENSGALG00000022183 (Gallus gallus)   MSH3 (2 of 2) (Danio rerio)   Msh3 (Rattus norvegicus)   msh3 (Xenopus laevis)   MSH3 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term reciprocal meiotic recombination, DNA binding, protein binding, DNA repair, damaged DNA binding, nuclear chromosome, single-stranded DNA binding, MutSbeta complex, mismatched DNA binding, meiotic mismatch repair, ATP binding, Y-form DNA binding, DNA-dependent ATPase activity, mismatch repair, maintenance of DNA repeat elements, nucleotide binding, enzyme binding, dinucleotide repeat insertion binding, somatic recombination of immunoglobulin gene segments, dinucleotide insertion or deletion binding, positive regulation of helicase activity, oxidized purine DNA binding, centromeric DNA binding, negative regulation of DNA recombination, single guanine insertion binding, loop DNA binding, double-strand/single-strand DNA junction binding
InterPro Term DNA_mismatch_repair_MutS_core, DNA_mismatch_repair_MutS_clamp, DNA_mismatch_repair_MutS-lik_N, DNA_mismatch_repair_MutS_connt, DNA_mismatch_repair_MutS_C
UniProt Accession P20585, F5GXK1
Gene-Disease Assocation ENDOMETRIAL CANCER
Search EB-eye ENSG00000113318
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-GEOD-22541, E-MEXP-1251, ... (22 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-19397, ... (35 experiments)

Factor Value U/D Experiments
SW480
3
E-MEXP-1014, E-GEOD-18005, E-MTAB-37
HT1080
2
E-GEOD-20089, E-MTAB-37
HCC38
2
E-MTAB-37, E-MTAB-62
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
DU145
2
E-GEOD-17482, E-GEOD-20089
MCF-10A
2
E-GEOD-14990, E-TABM-420
363 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-GEOD-360, E-GEOD-4219, E-GEOD-13909, ... (41 experiments)

Factor Value U/D Experiments
dendritic cell
2
E-GEOD-3982, E-GEOD-360
mononuclear
2
E-GEOD-13987, E-GEOD-26672
monocyte
1
2
E-GEOD-8286, E-GEOD-11755, E-GEOD-5099
central memory T cell
1
E-GEOD-3982
CXCR4 negative
1
E-GEOD-15893
erythropoietic
1
E-GEOD-9894
75 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-MEXP-2280, ... (53 experiments)

Factor Value U/D Experiments
prostate carcinoma
3
E-MTAB-62, E-MTAB-37, E-MEXP-2034
myxoid liposarcoma
2
E-GEOD-6481, E-MTAB-62
benign prostatic hyperplasia
2
E-MEXP-2034, E-MEXP-1243
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
breast cancer
2
E-MTAB-62, E-GEOD-22544
colon carcinoma
2
E-MTAB-62, E-GEOD-3726
176 more value(s).


Compound treatment

studied in E-GEOD-5258, E-TABM-782, E-GEOD-3720, E-GEOD-5824, E-TABM-868, ... (20 experiments)

Factor Value U/D Experiments
lipopolysaccharide
3
E-TABM-868, E-MEXP-1958, E-GEOD-3720
not specified
1
E-GEOD-20081
phoshate buffered saline
1
E-GEOD-3720
cigarette smoke
1
E-TABM-127
estradiol
1
E-GEOD-20081
actinomycin D
2
1
E-GEOD-6400
21 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-21374, E-GEOD-2034, ... (11 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, E-GEOD-22148, ... (8 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Er ihc
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, E-MTAB-108, ... (8 experiments)

Genotype
studied in E-TABM-763, E-TABM-1029, E-GEOD-3494, E-GEOD-2466, E-GEOD-21750, ... (12 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-1220, E-GEOD-6432, E-MEXP-2657, E-TABM-127, E-MEXP-1446, ... (8 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-MEXP-2069, E-GEOD-1926, ... (34 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-980, ... (6 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-TABM-321

Ki67 ihc
studied in E-GEOD-21653

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-22309, E-GEOD-21750, E-GEOD-1460, E-GEOD-3982, E-MEXP-1403 ... (5 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Pr ihc
studied in E-GEOD-21653

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-21837, E-GEOD-19445, E-GEOD-19246

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-18791, E-GEOD-10896, E-GEOD-17204

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-19246, E-GEOD-19815, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-3494, E-TABM-43, E-GEOD-1561, ... (7 experiments)

Tumor size
studied in E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.321 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM